JP2005533748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533748A5 JP2005533748A5 JP2003574192A JP2003574192A JP2005533748A5 JP 2005533748 A5 JP2005533748 A5 JP 2005533748A5 JP 2003574192 A JP2003574192 A JP 2003574192A JP 2003574192 A JP2003574192 A JP 2003574192A JP 2005533748 A5 JP2005533748 A5 JP 2005533748A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- substituted
- chemotherapeutic agent
- heterocycle
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 29
- 239000002246 antineoplastic agent Substances 0.000 claims 21
- 229940127089 cytotoxic agent Drugs 0.000 claims 21
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 239000012825 JNK inhibitor Substances 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- -1 cisplatinum Chemical compound 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 229940118135 JNK inhibitor Drugs 0.000 claims 4
- 210000000481 breast Anatomy 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000001118 alkylidene group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 210000001508 eye Anatomy 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 230000001850 reproductive effect Effects 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 125000004963 sulfonylalkyl group Chemical group 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 125000004001 thioalkyl group Chemical group 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 229940126161 DNA alkylating agent Drugs 0.000 claims 1
- 239000012624 DNA alkylating agent Substances 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000029749 Microtubule Human genes 0.000 claims 1
- 108091022875 Microtubule Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 1
- 125000002431 aminoalkoxy group Chemical group 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002257 antimetastatic agent Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000138 intercalating agent Substances 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 210000004688 microtubule Anatomy 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36270502P | 2002-03-08 | 2002-03-08 | |
| PCT/US2003/006894 WO2003075917A1 (en) | 2002-03-08 | 2003-03-07 | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| US10/384,440 US7351729B2 (en) | 2002-03-08 | 2003-03-07 | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005533748A JP2005533748A (ja) | 2005-11-10 |
| JP2005533748A5 true JP2005533748A5 (OSRAM) | 2006-04-27 |
Family
ID=27807974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574192A Pending JP2005533748A (ja) | 2002-03-08 | 2003-03-07 | 増殖性障害および癌を治療、予防、または管理するための併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7351729B2 (OSRAM) |
| EP (1) | EP1487436A4 (OSRAM) |
| JP (1) | JP2005533748A (OSRAM) |
| AU (1) | AU2003217961B2 (OSRAM) |
| CA (1) | CA2478338A1 (OSRAM) |
| NZ (1) | NZ535349A (OSRAM) |
| WO (1) | WO2003075917A1 (OSRAM) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| JP2005522215A (ja) * | 2002-04-12 | 2005-07-28 | セルジーン・コーポレーション | 幹細胞及び前駆細胞の分化のモジュレーション、アッセイ、並びにそれらの使用 |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| MXPA04011851A (es) * | 2002-05-30 | 2005-03-31 | Celgene Corp | Metodos para utilizar inhibidores de jnk o mkk para modular diferenciacion de celula y para tratar desordenes mieloproliferativos y sindromes mielodispl??sticos. |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
| KR20050072790A (ko) * | 2002-11-06 | 2005-07-12 | 셀진 코포레이션 | 골수증식 질환의 치료 및 관리를 위한 선택적 시토킨 억제약물의 사용 방법 및 이를 포함하는 조성물 |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US20050267144A1 (en) * | 2003-01-06 | 2005-12-01 | Eugene Mandrea | Methods of stimulating immune response in virally infected individuals |
| US20060183767A1 (en) * | 2003-01-06 | 2006-08-17 | Eugene Mandrea | Methods of stimulating immune response in certain individuals |
| US7893083B2 (en) * | 2003-01-06 | 2011-02-22 | Eugene Mandrea | Method of treating genital herpes |
| US20070020234A1 (en) * | 2003-07-07 | 2007-01-25 | Vande Woude George F | Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
| CN1901903A (zh) * | 2003-11-06 | 2007-01-24 | 细胞基因公司 | 用于治疗和控制石棉相关性疾病和病症的包含jnk抑制剂的组合物以及其使用方法 |
| US7498322B2 (en) * | 2004-03-12 | 2009-03-03 | Entremed, Inc. | Antiangiogenic agents |
| US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
| AU2005228410A1 (en) | 2004-03-29 | 2005-10-13 | University Of South Florida | Effective treatment of tumors and cancer with triciribine and related compounds |
| US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
| US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| US20100173864A1 (en) * | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
| MXPA06012701A (es) * | 2004-05-05 | 2007-02-14 | Celgene Corp | Metodo de utilizacion y composiciones que comprenden farmacos inhibidores de citocina selectivos para el tratamiento y manejo de enfermedades mieloproliferativas. |
| EP1773327A1 (en) * | 2004-07-27 | 2007-04-18 | Novartis AG | Inhibitors of hsp90 |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| US20060204474A1 (en) * | 2005-02-25 | 2006-09-14 | Coroneo Minas T | Treatment of epithelial layer lesions |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 ｊｎｋ 억제제 |
| BRPI0613042A2 (pt) * | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| CN1870631B (zh) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | 媒体网关的门控方法 |
| US20070185069A1 (en) * | 2005-11-14 | 2007-08-09 | Plum Stacy M | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents |
| EP1956908A2 (en) * | 2005-12-08 | 2008-08-20 | Cytokinetics, Inc. | Certain compositions and methods of treatment |
| CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
| AU2007227256B2 (en) * | 2006-03-20 | 2012-10-04 | Entremed, Inc. | Disease modifying anti-arthritic activity of 2-methoxyestradiol |
| WO2007139930A2 (en) * | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Drug combinations with substituted diaryl ureas for the treatment of cancer |
| US20080070855A1 (en) * | 2006-09-20 | 2008-03-20 | James Pitzer Gills | Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes |
| WO2008116161A2 (en) * | 2007-03-22 | 2008-09-25 | The General Hospital Corporation | Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states |
| JP5688840B2 (ja) * | 2007-09-10 | 2015-03-25 | ボストン バイオメディカル， インコーポレイテッド | 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤 |
| EP2047858A1 (en) * | 2007-10-10 | 2009-04-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Combination products for treating cancer |
| WO2009052187A2 (en) * | 2007-10-15 | 2009-04-23 | Stokes John P | Convergent well irradiating plaque for choroidal melanoma |
| TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| WO2009143865A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| CA2741089A1 (en) | 2008-10-22 | 2010-04-29 | Genentech, Inc. | Modulation of axon degeneration |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| US8546433B2 (en) * | 2009-01-16 | 2013-10-01 | Rigel Pharmaceuticals, Inc. | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
| US8663210B2 (en) | 2009-05-13 | 2014-03-04 | Novian Health, Inc. | Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy |
| JP2013508401A (ja) * | 2009-10-22 | 2013-03-07 | ジェネンテック， インコーポレイテッド | 軸索変性の調節 |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| JP5857056B2 (ja) | 2010-10-14 | 2016-02-10 | ザイジェン インフラメーション エルティーディー | 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用 |
| US8487378B2 (en) * | 2011-01-21 | 2013-07-16 | Taiwan Semiconductor Manufacturing Company, Ltd. | Non-uniform channel junction-less transistor |
| CN103501824A (zh) * | 2011-02-18 | 2014-01-08 | Uab研究基金会 | 与嘌呤核苷磷酸化酶或核苷水解酶的前体药物的改进的治疗用途相关的应用 |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| RU2488173C1 (ru) * | 2012-04-26 | 2013-07-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук | Способ создания биологической модели умеренного торможения роста опухоли и метастазов карциномы легких льюис с продолжительной циклофосфаниндуцированной лейкопенией у мышей |
| US9166912B2 (en) | 2013-02-25 | 2015-10-20 | Google Inc. | Translating network forwarding plane models into target implementation using sub models and hints |
| US9172604B1 (en) | 2013-02-25 | 2015-10-27 | Google Inc. | Target mapping and implementation of abstract device model |
| RU2015136387A (ru) * | 2013-02-28 | 2017-03-30 | Дженентек, Инк. | Способы модуляции стабильности dlk |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
| BR112015023256A2 (pt) | 2013-03-13 | 2017-07-18 | Oncoceutics Inc | terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona. |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| CN106163524B (zh) * | 2013-11-15 | 2019-11-08 | 昂克希尔迪克斯有限公司 | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法 |
| IL295286B2 (en) | 2015-01-30 | 2024-10-01 | Oncoceutics Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs thereof, and salts thereof and methods for their use in therapy |
| WO2016141381A2 (en) * | 2015-03-05 | 2016-09-09 | University Of Notre Dame Du Lac | Potentiators of beta-lactam antibiotics |
| CN104860948B (zh) * | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
| EP3187190A1 (en) * | 2015-12-31 | 2017-07-05 | Erytech Pharma | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| BR112019006949A2 (pt) | 2016-10-05 | 2019-07-02 | Tohoku University | droga efetiva para o método de administração de medicamentos linfógenos |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020205608A1 (en) * | 2019-03-29 | 2020-10-08 | Emory University | Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| TW202115024A (zh) | 2019-08-14 | 2021-04-16 | 美商英塞特公司 | 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物 |
| CN119930610A (zh) | 2019-10-11 | 2025-05-06 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| US20250268920A1 (en) * | 2022-04-20 | 2025-08-28 | The Penn State Research Foundation | Use of androgen receptor-mediated mechanisms in the treatment of acute myeloid leukemia |
| CN114652715B (zh) * | 2022-04-29 | 2023-04-25 | 奎马特里克斯有限公司 | 联合疗法 |
Family Cites Families (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1266763B (de) | 1965-07-27 | 1968-04-25 | Kalle Ag | Verfahren zur Herstellung von in 3-Stellung substituierten Indol- und Indazolderivaten |
| CH538528A (de) | 1968-11-07 | 1973-06-30 | Hoechst Ag | Verfahren zur Herstellung von faserreaktiven Farbstoffen |
| DE2200127A1 (de) | 1972-01-03 | 1973-07-12 | Basf Ag | Verfahren zur herstellung von dichlor1,1'-dianthrachinonylen und deren derivaten |
| US3994890A (en) | 1974-01-31 | 1976-11-30 | Chugai Seiyaku Kabushiki Kaisha | 1-Aminoalkyl, 3-phenyl indazoles |
| DE2558813C2 (de) | 1975-12-27 | 1984-10-31 | Hoechst Ag, 6230 Frankfurt | Lichtempfindliches Gemisch mit synergistischem Initiatorsystem |
| IL48824A (en) | 1976-01-12 | 1980-05-30 | Yissum Res Dev Co | Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type |
| US4198518A (en) | 1977-09-02 | 1980-04-15 | Ciba-Geigy Corporation | Process for the production of 3-substituted pyrazolanthrones |
| JPS57109787A (en) | 1980-12-26 | 1982-07-08 | Chugai Pharmaceut Co Ltd | Pyrazoloindazole derivative |
| JPH0625311B2 (ja) | 1985-07-09 | 1994-04-06 | 住友化学工業株式会社 | 分散型水不溶性染料組成物 |
| US4876252A (en) | 1986-01-13 | 1989-10-24 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
| US4788195A (en) | 1986-01-13 | 1988-11-29 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
| US4966622A (en) | 1988-04-12 | 1990-10-30 | Ciba-Geigy Corporation | N-phenyl-N-pyrimidin-2-ylureas |
| US4973690A (en) | 1988-04-12 | 1990-11-27 | Ciba-Geigy Corporation | Novel ureas |
| JP2515162B2 (ja) | 1990-02-23 | 1996-07-10 | 富士写真フイルム株式会社 | メチン化合物 |
| US5081122A (en) | 1990-03-05 | 1992-01-14 | Sterling Drug Inc. | Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof |
| US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
| GB9016449D0 (en) | 1990-07-26 | 1990-09-12 | Ici Plc | Anionic compounds |
| EP0494774A1 (en) | 1991-01-11 | 1992-07-15 | MERCK SHARP & DOHME LTD. | Indazole-substituted fivemembered heteroaromatic compounds |
| DE69230387T2 (de) | 1991-04-22 | 2000-06-29 | Fuji Photo Film Co., Ltd. | Photographische Silberhalogenidmaterialien und Verfahren zu ihrer Verarbeitung |
| NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| JP2692021B2 (ja) | 1991-09-13 | 1997-12-17 | 富士写真フイルム株式会社 | ハロゲン化銀感光材料 |
| WO1993008167A1 (fr) | 1991-10-24 | 1993-04-29 | Nippon Soda Co., Ltd. | Nouveau derive heterocyclique et bactericide agrohorticole le renfermant |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| IL103932A (en) | 1992-11-30 | 1997-02-18 | Yissum Res & Dev | Fatty acid and pharmaceutical compositions containing them |
| FR2709912B1 (fr) | 1993-09-09 | 1995-10-20 | Renault | Procédé et dispositif de traitement homogène par micro-ondes de matériaux. |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| IT1271267B (it) | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
| IT1271266B (it) | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
| FR2728583B1 (fr) | 1994-12-23 | 1997-01-31 | Rhone Poulenc Chimie | Compositions detergentes a base d'un copolymere silicate organomineral, utilisation dudit copolymere comme agent alcalin non corrosif et protecteur du verre et de la vaisselle |
| US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| US5605906A (en) | 1995-03-24 | 1997-02-25 | Merck Frosst Canada, Inc. | Cannabinoid receptor agonists |
| FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| US6013948A (en) * | 1995-11-27 | 2000-01-11 | Micron Technology, Inc. | Stackable chip scale semiconductor package with mating contacts on opposed surfaces |
| FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| AU1618697A (en) | 1996-02-06 | 1997-08-28 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| KR20000052948A (ko) | 1996-11-01 | 2000-08-25 | 메리 이. 보울러 | 살진균성 환식 아미드 |
| ES2213892T3 (es) | 1997-01-21 | 2004-09-01 | Smithkline Beecham Corporation | Nuevos moduladores del receptor de canabinoides. |
| FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| BRPI9807848B8 (pt) | 1997-02-21 | 2016-05-31 | Bayer Schering Pharma Ag | compostos de arilsulfonamidas e análogos, bem como composição farmacêutica e uso dos mesmos. |
| DE19706903A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1 |
| EP0979228A4 (en) | 1997-03-18 | 2000-05-03 | Smithkline Beecham Corp | CANNABINOID RECEPTOR AGONISTS |
| EP0973767A1 (en) | 1997-03-31 | 2000-01-26 | Dupont Pharmaceuticals Company | Indazoles of cyclic ureas useful as hiv protease inhibitors |
| US5804592A (en) | 1997-05-30 | 1998-09-08 | Unimed Pharmaceuticals, Inc. | Method for improving disturbed behavior and elevating mood in humans |
| AU8181098A (en) | 1997-07-03 | 1999-01-25 | Du Pont Pharmaceuticals Company | Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| WO1999002499A1 (en) | 1997-07-11 | 1999-01-21 | Japan Tobacco Inc. | Quinoline compounds and medicinal uses thereof |
| US5939429A (en) | 1997-09-30 | 1999-08-17 | Virginia Commonwealth University | Cardiovascular uses of cannabinoid compounds |
| AU1394899A (en) | 1997-11-10 | 1999-05-31 | Research Foundation Of The State University Of New York, The | Opiate, cannabinoid, and estrogen receptors |
| WO1999026612A1 (en) | 1997-11-21 | 1999-06-03 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
| US6162613A (en) | 1998-02-18 | 2000-12-19 | Vertex Pharmaceuticals, Inc. | Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases |
| EP1066235B1 (en) | 1998-04-03 | 2003-10-01 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Synthetic endogenous cannabinoid analogues and uses thereof |
| GB9807639D0 (en) | 1998-04-14 | 1998-06-10 | Kennedy Rheumatology Inst | Anti-inflammatory agents |
| ATE212552T1 (de) | 1998-04-17 | 2002-02-15 | Tufts College | Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten |
| DE69920683T2 (de) | 1998-05-04 | 2005-04-07 | The University Of Connecticut, Farmington | Selektiv auf den CB2-Rezeptor wirkende Cannabinoide |
| JP2002513562A (ja) | 1998-05-04 | 2002-05-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | 結晶化可能なｊｎｋ複合体 |
| EP1075470B1 (en) | 1998-05-04 | 2003-08-13 | The University Of Connecticut | Novel analgesic and immunomodulatory cannabinoids |
| US6348498B1 (en) | 1998-05-29 | 2002-02-19 | Neurosciences Research Foundation, Inc. | Control of pain with endogenous cannabinoids |
| US6562833B1 (en) | 1998-06-10 | 2003-05-13 | Basf Aktiengesellschaft | Use of 2-(n-phenylamino)pyrimidines as fungicides, and novel 2-(n-phenylamino) pyrimidines |
| DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
| HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
| JP2002523498A (ja) | 1998-08-29 | 2002-07-30 | アストラゼネカ・アクチエボラーグ | ピリミジン化合物 |
| FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| GB9819860D0 (en) | 1998-09-12 | 1998-11-04 | Zeneca Ltd | Chemical compounds |
| IT1302264B1 (it) | 1998-09-24 | 2000-09-05 | Innovet Italia Srl | Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi |
| GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1049474A4 (en) | 1998-11-24 | 2004-12-29 | Univ Connecticut | CANNABIMIMETIC LIPID AMIDES FOR USE AS MEDICINES |
| US6127376A (en) | 1998-12-04 | 2000-10-03 | Berlex Laboratories, Inc. | Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
| CA2354591A1 (en) | 1998-12-17 | 2000-06-22 | F. Hoffmann-La Roche Ag | 4-aryloxindoles as inhibitors of jnk protein kinases |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| JP2000256323A (ja) | 1999-01-08 | 2000-09-19 | Japan Tobacco Inc | ２−オキソキノリン化合物及びその医薬用途 |
| GB2345486A (en) | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| EP1144390A2 (en) | 1999-01-22 | 2001-10-17 | Amgen Inc., | Kinase inhibitors |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| FR2789078B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Sa | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| AU3910700A (en) | 1999-03-22 | 2000-10-09 | Immugen Pharmaceuticals, Inc. | Treatment of immune diseases |
| GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
| AU4483000A (en) | 1999-04-23 | 2000-11-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) |
| WO2000075118A1 (en) | 1999-06-03 | 2000-12-14 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| ES2368199T3 (es) | 1999-07-07 | 2011-11-15 | Innovet Italia S.R.L. | Derivados covalentes de alcanolamidas de ácidos monocarboxílicos y dicarboxílicos funcionalmente activos en el receptor cannabinoide cb2. |
| CA2381882C (en) | 1999-08-13 | 2011-01-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| NZ517578A (en) | 1999-08-19 | 2004-02-27 | Signal Pharm Inc | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| DE60038687T2 (de) | 1999-09-14 | 2009-05-28 | Shionogi & Co., Ltd. | 2-imino-1,3-thiazin-derivate |
| EP1088822A1 (en) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonyl hydrazide derivatives |
| FR2799124B1 (fr) | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
| CA2286442A1 (en) | 1999-10-15 | 2001-04-15 | Universite De Montreal | Compositions for increasing the concentration of cannabinoids as vasodilators and cardioprotectors againts ischaemia |
| EP1224155B1 (en) | 1999-10-18 | 2007-02-21 | The University Of Connecticut | Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| JP2003512357A (ja) | 1999-10-18 | 2003-04-02 | ユニバーシティ オブ コネチカット | カンナビノイドレセプタ拮抗物質としてのピラゾール誘導体 |
| JP2003512326A (ja) | 1999-10-18 | 2003-04-02 | ユニヴァーシティ オブ コネチカット | カンナビノイド相似インドール誘導体 |
| WO2001028329A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Peripheral cannabinoid receptor (cb2) selective ligands |
| CA2387846A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| IL132661A (en) | 1999-10-31 | 2008-11-26 | Raphael Mechoulam | Agonists specific for peripheral cannabinoid receptors |
| FR2800372B1 (fr) | 1999-11-03 | 2001-12-07 | Sanofi Synthelabo | Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant |
| FR2800375B1 (fr) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| YU54202A (sh) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| FR2804604B1 (fr) | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
| US6653304B2 (en) | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| ES1045342Y (es) | 2000-02-11 | 2001-02-16 | Alvarez Manuel Couto | Expositor giratorio para postales, fotos y similares. |
| WO2001064212A1 (en) | 2000-03-01 | 2001-09-07 | University College London | Modulators of the endocannabinoid uptake and of the vallinoid receptors |
| FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| WO2001070700A1 (en) | 2000-03-23 | 2001-09-27 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| DE10015866A1 (de) | 2000-03-30 | 2001-10-11 | Bayer Ag | Aryl- und Heteroarylsulfonate |
| US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
| AU2001264930A1 (en) | 2000-05-23 | 2001-12-03 | The Regents Of The University Of California | A novel treatment for cough |
| AU2001266611A1 (en) | 2000-06-01 | 2001-12-11 | Merck & Co., Inc. | Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors |
| TWI302913B (en) | 2000-06-15 | 2008-11-11 | Schering Corp | Thrombin receptor antagonists |
| IL136839A (en) | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
| WO2001098289A1 (en) | 2000-06-22 | 2001-12-27 | Pharmos Corporation | Novel non-psychotropic cannabinoids |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| NZ523839A (en) | 2000-08-01 | 2005-07-29 | Ono Pharmaceutical Co | 3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient |
| DE10042663A1 (de) | 2000-08-31 | 2002-03-14 | Deutsche Telekom Ag | Eletronenspektrometer |
| WO2002024630A1 (en) | 2000-09-22 | 2002-03-28 | Eli Lilly And Company | Pharmaceutical compounds useful as modulators of endocannabinoid-mediated response |
| DE10047486A1 (de) | 2000-09-26 | 2002-04-11 | Bayer Ag | Phenoxyphenyl Alkansulfonate |
| FR2814678B1 (fr) | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| AUPR118000A0 (en) | 2000-11-02 | 2000-11-23 | Amrad Operations Pty. Limited | Therapeutic molecules and methods |
| FR2816938B1 (fr) | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
| US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| US20020077322A1 (en) | 2000-12-15 | 2002-06-20 | Ayoub George S. | Protection of neurons against glutamate-induced damage in glaucoma and other conditions |
| CA2433158C (en) | 2000-12-28 | 2011-05-10 | Shionogi & Co., Ltd. | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor |
| EP1361876A4 (en) | 2001-01-26 | 2004-03-31 | Univ Connecticut | NEW CANNABIMIMETIC LIGANDS |
| US7173027B2 (en) | 2001-01-29 | 2007-02-06 | University Of Connecticut | Receptor selective cannabimimetic aminoalkylindoles |
| US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| US6987184B2 (en) | 2001-02-15 | 2006-01-17 | Signal Pharmaceuticals, Llc | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related |
| GB0104268D0 (en) | 2001-02-21 | 2001-04-11 | Unilever Plc | Antiperspirant or deodorant compositions |
| JP4188694B2 (ja) | 2001-03-08 | 2008-11-26 | 塩野義製薬株式会社 | １，３−チアジン誘導体を含有する医薬組成物 |
| WO2002080903A1 (en) | 2001-04-06 | 2002-10-17 | The Board Of Trustees Of The University Of Illinois | Functional role for cannabinoids in autonomic stability during sleep |
| SE0101387D0 (sv) | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | Novel compounds |
| WO2002085396A1 (en) | 2001-04-24 | 2002-10-31 | President And Fellows Of Harvard College | Inhibition of jun kinase |
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| MXPA04011851A (es) | 2002-05-30 | 2005-03-31 | Celgene Corp | Metodos para utilizar inhibidores de jnk o mkk para modular diferenciacion de celula y para tratar desordenes mieloproliferativos y sindromes mielodispl??sticos. |
-
2003
- 2003-03-07 JP JP2003574192A patent/JP2005533748A/ja active Pending
- 2003-03-07 WO PCT/US2003/006894 patent/WO2003075917A1/en not_active Ceased
- 2003-03-07 EP EP03713937A patent/EP1487436A4/en not_active Withdrawn
- 2003-03-07 CA CA002478338A patent/CA2478338A1/en not_active Abandoned
- 2003-03-07 US US10/384,440 patent/US7351729B2/en not_active Expired - Fee Related
- 2003-03-07 NZ NZ535349A patent/NZ535349A/en unknown
- 2003-03-07 AU AU2003217961A patent/AU2003217961B2/en not_active Ceased
-
2007
- 2007-02-09 US US11/704,665 patent/US20070149571A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533748A5 (OSRAM) | ||
| US7612052B2 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| JP2011529474A (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2010500376A5 (OSRAM) | ||
| MXPA06000191A (es) | Combinacion de los inhibidores de src cinasa y agentes quimioterapeuticos para el tratamiento de enfermedades proliferativas. | |
| JP2005535594A5 (OSRAM) | ||
| RS50692B (sr) | Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera | |
| AU2002328921A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| AU775305B2 (en) | Combination therapy using pentafluorobenzenesulfonamide and platin compound | |
| CA2553704A1 (en) | Substituted benzimidazoles and their use for inducing apoptosis | |
| PT2754441E (pt) | Composição para a prevenção e tratamento de cancro do pulmão de não pequenas células, contendo derivados de pirazino-triazina | |
| JP2007510671A5 (OSRAM) | ||
| RU2006138864A (ru) | Ингибиторы митотического кинезина | |
| JP2009292837A (ja) | より効能が大きく副作用の少ない癌治療方法 | |
| JPWO2022014640A5 (OSRAM) | ||
| JP2011514356A5 (OSRAM) | ||
| IL152956A (en) | Combined Pharmaceutical Preparations Containing Transformed History Of Acryloyl Dystamycin And Alkylation Materials And Uses | |
| ES2285251T3 (es) | Uso de derivados 4-piridilmetilftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos. | |
| JP2005029573A (ja) | 腫瘍転移抑制剤 | |
| JP2003535874A (ja) | 置換アクリロイルジスタマイシン誘導体、タキサン類及び／又は代謝拮抗剤を含む腫瘍に対する併用療法 | |
| JP2011502985A5 (OSRAM) | ||
| JPWO2002092096A1 (ja) | 抗腫瘍剤 | |
| JP2006502195A5 (OSRAM) | ||
| AU2008203233B2 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| AU2012331125A1 (en) | 2-carboxamide cycloamino urea derivatives for use in treating VEGF - dependent diseases |